Overexpression of Cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma

BMC Surgery

Zhe-Sheng Wen¹  Mu-Sheng Zeng²  Zhi-Liang Huang¹  Jie-Hua He⁵  Li-Ru He⁴  Rong-Zhen Luo⁵  Xun Cao³  Gang Ma³  You-Fang Chen¹ 

[1] Department of Thoracic Oncology, Cancer Center, Sun Yet-Sen University, No.651, Dongfeng Road East, Guangzhou, China;State Key Laboratory of Oncology in South China, Cancer Center, Sun Yet-Sen University, No.651, Dongfeng Road East, Guangzhou, China;Department of Critical Care Medicine, Cancer Center, Sun Yet-Sen University, No.651, Dongfeng Road East, Guangzhou, China;Department of Radiation Oncology, Cancer Center, Sun Yet-Sen University, No.651, Dongfeng Road East, Guangzhou, China;Department of Pathology, Cancer Center, Sun Yet-Sen University, No.651, Dongfeng Road East, Guangzhou, China

关键词: Prognosis;    Immunohistochemistry;    Cystatin SN;    Esophageal squamous cell carcinoma;   

Others  :  866929
DOI  :  10.1186/1471-2482-13-15

 received in 2013-01-05, accepted in 2013-05-23,  发布年份 2013

【 摘 要 】

Background

Cystatin SN is a secreted protein and a cysteine proteinase inhibitor. It has been considered to be a tumor marker for gastrointestinal tract cancer in several functional researches. However, the clinicopathological and prognostic significance of Cystatin SN expression in esophageal squamous cell carcinoma (ESCC) has not been elucidated.

Methods

In our study, the expression of Cystatin SN was detected in 209 surgically resected ESCC tissues and 170 peritumoral normal esophageal mucosae by immunohistochemistry. The prognostic significance of Cystatin SN expression was analysed with Kaplan-Meier plots and the Cox proportional hazards regression models.

Results

The results showed that the immunostaining of Cystatin SN in ESCC tissues was less intense than that in the normal control tissue (P < 0.001). Compared with patients with low tumoral Cystatin SN expression, ESCC patients with tumors high-expression Cystatin SN exhibited increased disease-free survival (DFS) and overall survival (OS) (P < 0.001 and P < 0.001, respectively). Furthermore, the expression level of Cystatin SN could further stratify the ESCC patients by survival (DFS and OS) in the stage II subgroup (P < 0.001 and P < 0.001, respectively). Multivariate analyses showed that Cystatin SN expression, N status and differentiation were independent and significant predictors of survival.

Conclusions

We concluded that ESCC patients whose tumors express high levels of Cystatin SN have favourable survival compared with those patients with low Cystatin SN expression. Tumoral Cystatin SN expression may be an independent predictor of survival for patients with resectable ESCCs.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Fig. 3.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Guo P, Li K: Trends in esophageal cancer mortality in China during 1987–2009: age, period and birth cohort analyzes. Cancer Epidemiol 2012, 36(2):99-105.
• [3]Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao YL, Taylor PR: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer J Int du cancer 2005, 113(3):456-463.
• [4]Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252.
• [5]Koblinski JE, Ahram M, Sloane BF: Unraveling the role of proteases in cancer. Clinica Chimica Acta; Int J Clin Chem 2000, 291(2):113-135.
• [6]Choi EH, Kim JT, Kim JH, Kim SY, Song EY, Kim JW, Yeom YI, Kim IH, Lee HG: Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer. Clinica Chimica Acta; Int J Clin Chem 2009, 406(1–2):45-51.
• [7]Szumilo J, Burdan F, Zinkiewicz K, Dudka J, Klepacz R, Dabrowski A, Korobowicz E: Expression of syndecan-1 and cathepsins D and K in advanced esophageal squamous cell carcinoma. Folia histochemica et cytobiologica/Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2009, 47(4):571-578.
• [8]Andl CD, McCowan KM, Allison GL, Rustgi AK: Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia 2010, 12(6):485-498.
• [9]Dickinson DP, Thiesse M, Hicks MJ: Expression of type 2 cystatin genes CST1-CST5 in adult human tissues and the developing submandibular gland. DNA Cell Biol 2002, 21(1):47-65.
• [10]Turk B, Turk D, Turk V: Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 2000, 1477(1–2):98-111.
• [11]Vigneswaran N, Wu J, Zacharias W: Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis. Oral Oncol 2003, 39(6):559-568.
• [12]Turk B, Turk V, Turk D: Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997, 378(3–4):141-150.
• [13]Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J, et al.: Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int J Cancer J Int du Cancer 1999, 83(4):526-531.
• [14]Cox JL, Sexton PS, Green TJ, Darmani NA: Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res 1999, 9(4):369-374.
• [15]Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res: An Official Journal of the American Association for Cancer Research 2000, 6(2):505-511.
• [16]Morita M, Yoshiuchi N, Arakawa H, Nishimura S: CMAP: a novel cystatin-like gene involved in liver metastasis. Cancer Res 1999, 59(1):151-158.
• [17]Schagdarsurengin U, Pfeifer GP, Dammann R: Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 2007, 26(21):3089-3094.
• [18]Utsunomiya T, Hara Y, Kataoka A, Morita M, Arakawa H, Mori M, Nishimura S: Cystatin-like metastasis-associated protein mRNA expression in human colorectal cancer is associated with both liver metastasis and patient survival. Clin Cancer Res: An Official J Am Assoc Cancer Res 2002, 8(8):2591-2594.
• [19]Alvarez-Diaz S, Valle N, Garcia JM, Pena C, Freije JM, Quesada V, Astudillo A, Bonilla F, Lopez-Otin C, Munoz A: Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest 2009, 119(8):2343-2358.
• [20]Parle-McDermott A, McWilliam P, Tighe O, Dunican D, Croke DT: Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines. Br J Cancer 2000, 83(6):725-728.
• [21]Yoneda K, Iida H, Endo H, Hosono K, Akiyama T, Takahashi H, Inamori M, Abe Y, Yoneda M, Fujita K, et al.: Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009, 35(1):33-40.
• [22]Cao X, Li Y, Luo RZ, He LR, Yang J, Zeng MS, Wen ZS: Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Ann Thorac Surg 2012, 93(5):1674-1680.
• [23]Fermento ME, Gandini NA, Lang CA, Perez JE, Maturi HV, Curino AC, Facchinetti MM: Intracellular distribution of p300 and its differential recruitment to aggresomes in breast cancer. Exp Mol Pathol 2010, 88(2):256-264.
• [24]Jiang S, Li Y, Zhu YH, Wu XQ, Tang J, Li Z, Feng GK, Deng R, Li DD, Luo RZ, et al.: Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Sci 2011, 102(8):1568-1575.
• [25]Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
• [26]Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, Groom AC: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994, 54(17):4791-4797.
• [27]Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997, 94(4):1402-1407.
• [28]Strojan P, Oblak I, Svetic B, Smid L, Kos J: Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br J Cancer 2004, 90(10):1961-1968.
• [29]Chapman HA, Riese RJ, Shi GP: Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997, 59:63-88.
• [30]Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 1999, 248(1):30-43.
• [31]Gaur P, Hofstetter WL, Bekele BN, Correa AM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Rice TW, Swisher SG: Comparison between established and the Worldwide Esophageal Cancer Collaboration staging systems. Ann Thorac Surg 2010, 89(6):1797-1803. 1804 e1791-1793; discussion 1803–1794
• [32]Takeno S, Noguchi T, Takahashi Y, Fumoto S, Shibata T, Kawahara K: Assessment of clinical outcome in patients with esophageal squamous cell carcinoma using TNM classification score and molecular biological classification. Ann Surg Oncol 2007, 14(4):1431-1438.